SG11201602331QA - Compositions and methods utilizing lysophosphatidylcholine scaffolds - Google Patents

Compositions and methods utilizing lysophosphatidylcholine scaffolds

Info

Publication number
SG11201602331QA
SG11201602331QA SG11201602331QA SG11201602331QA SG11201602331QA SG 11201602331Q A SG11201602331Q A SG 11201602331QA SG 11201602331Q A SG11201602331Q A SG 11201602331QA SG 11201602331Q A SG11201602331Q A SG 11201602331QA SG 11201602331Q A SG11201602331Q A SG 11201602331QA
Authority
SG
Singapore
Prior art keywords
compositions
methods utilizing
lysophosphatidylcholine
scaffolds
lysophosphatidylcholine scaffolds
Prior art date
Application number
SG11201602331QA
Inventor
Nam Long Nguyen
Robert Zahler
David Lawrence Silver
Original Assignee
Univ Singapore
David Lawrence Silver
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Singapore, David Lawrence Silver filed Critical Univ Singapore
Publication of SG11201602331QA publication Critical patent/SG11201602331QA/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276Knock-out vertebrates
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544Phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052Small organic molecules
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • G01N33/5088Supracellular entities, e.g. tissue, organisms of vertebrates
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04Phospholipids, i.e. phosphoglycerides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Environmental Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
SG11201602331QA 2013-09-26 2014-09-26 Compositions and methods utilizing lysophosphatidylcholine scaffolds SG11201602331QA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361882693P 2013-09-26 2013-09-26
US201461973136P 2014-03-31 2014-03-31
US201461992822P 2014-05-13 2014-05-13
PCT/US2014/057871 WO2015048554A1 (en) 2013-09-26 2014-09-26 Compositions and methods utilizing lysophosphatidylcholine scaffolds

Publications (1)

Publication Number Publication Date
SG11201602331QA true SG11201602331QA (en) 2016-04-28

Family

ID=52744542

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201602331QA SG11201602331QA (en) 2013-09-26 2014-09-26 Compositions and methods utilizing lysophosphatidylcholine scaffolds

Country Status (9)

Country Link
US (2) US10175256B2 (en)
EP (2) EP3049429B1 (en)
JP (3) JP6692748B2 (en)
CN (2) CN105764917B (en)
AU (3) AU2014324651B2 (en)
CA (1) CA2925613A1 (en)
ES (1) ES2806751T3 (en)
SG (1) SG11201602331QA (en)
WO (1) WO2015048554A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3049429B1 (en) 2013-09-26 2020-05-06 National University of Singapore Compositions and methods utilizing lysophosphatidylcholine scaffolds
US10345302B2 (en) * 2017-02-19 2019-07-09 Sheng-He Huang Circulating astrocytes and MFSD2A as biomarkers
WO2018196011A1 (en) * 2017-04-29 2018-11-01 韩婷 Use of mfsd2a in preparing product for diagnosing purulent meningitis
US10555957B2 (en) 2017-05-10 2020-02-11 The Board Of Trustees Of The University Of Illinois Methods and compositions for enriching DHA levels in the brain
JP2021508343A (en) 2017-12-21 2021-03-04 エーケル バイオマリーン アンタークティク エーエス Lysophosphatidylcholine composition
CN109932511B (en) * 2019-03-22 2020-02-04 南昌大学第二附属医院 Urine exosome phospholipid marker for liver cancer screening and kit thereof
CN110361460A (en) * 2019-06-18 2019-10-22 湖北省农业科学院畜牧兽医研究所 A kind of discrimination method of laying duck stress situation
BR112021025477A2 (en) * 2019-06-20 2022-03-03 Aker Biomarine Antarctic As Parenteral lysophosphatidylcholine formulations like lpc-dha, lpc-epa and their uses in therapy
JP2023521598A (en) 2020-03-31 2023-05-25 エーケル バイオマリーン アンタークティク エーエス Krill oil composition enriched with LPC-DHA and LPC-EPA
JPWO2022045020A1 (en) 2020-08-25 2022-03-03
WO2022101678A2 (en) 2020-11-15 2022-05-19 Aker Biomarine Antarctic As Lysophospholipid formulations
WO2023166347A1 (en) * 2022-03-04 2023-09-07 Institut Pasteur Uptake mechanism of essential lysophospholipids into the brain and inhibition by endogenous-retroviral envelope protein
WO2023225249A1 (en) * 2022-05-20 2023-11-23 President And Fellows Of Harvard College Methods and compositions relating to treatment of cns diseases
KR20240011905A (en) * 2022-07-19 2024-01-29 크로다코리아 주식회사 Composition for preventing and improving memory loss comprising lysophospholipids derived from marine organism including Omega-3 fatty acid

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4431739A (en) 1979-11-05 1984-02-14 Genentech, Inc. Transformant bacterial culture capable of expressing heterologous protein
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
US4452720A (en) 1980-06-04 1984-06-05 Teijin Limited Fluorescent composition having the ability to change wavelengths of light, shaped article of said composition as a light wavelength converting element and device for converting optical energy to electrical energy using said element
US4439356A (en) 1981-03-03 1984-03-27 Syva Company Unsymmetrical fluorescein derivatives
US4874795A (en) 1985-04-02 1989-10-17 Yesair David W Composition for delivery of orally administered drugs and other substances
US5330900A (en) 1987-12-31 1994-07-19 Tropix, Inc. Chemiluminescent 3-(substituted adamant-2'-ylidene) 1,2-dioxetanes
US5066580A (en) 1988-08-31 1991-11-19 Becton Dickinson And Company Xanthene dyes that emit to the red of fluorescein
US5227487A (en) 1990-04-16 1993-07-13 Molecular Probes, Inc. Certain tricyclic and pentacyclic-hetero nitrogen rhodol dyes
US5750409A (en) 1991-11-18 1998-05-12 Boehringer Mannheim Gmbh Pentacyclic compounds and their use as absorption or fluorescent dyes
US5716814A (en) * 1996-02-02 1998-02-10 Biomolecular Products, Inc. Methods for making lysophosphatidylcholine
US5847162A (en) 1996-06-27 1998-12-08 The Perkin Elmer Corporation 4, 7-Dichlororhodamine dyes
US6080852A (en) 1996-06-27 2000-06-27 The Perkin-Elmer Corporation 4,7-dichlororhodamine dyes
US6008379A (en) 1997-10-01 1999-12-28 The Perkin-Elmer Corporation Aromatic-substituted xanthene dyes
US5936087A (en) 1997-11-25 1999-08-10 The Perkin-Elmer Corporation Dibenzorhodamine dyes
US20020150626A1 (en) * 2000-10-16 2002-10-17 Kohane Daniel S. Lipid-protein-sugar particles for delivery of nucleic acids
ATE386986T1 (en) 2001-07-06 2008-03-15 Lipomics Technologies Inc GENERATE, VIEW, INTERPRET AND USE A QUANTITATIVE DATABASE OF METABOLITES
FR2836829B1 (en) * 2002-03-11 2005-11-25 Bio Merieux USE OF L-ALPHA-LYSOPHOSPHATIDYLCHOLINE FOR DIFFERENTIATION OF MONOCYTES IN MATURE IN VITRO DENDRITIC CELLS
PT1551370E (en) * 2002-10-11 2008-02-07 Idea Ag Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
US20060222699A1 (en) 2005-03-29 2006-10-05 Jonathan Gilinski Flavored vegetarian cellulose capsule and methods for producing said capsule.
US20090131368A1 (en) * 2006-07-19 2009-05-21 Su Chen Mixtures of and methods of use for polyunsaturated fatty acid-containing phospholipids and alkyl ether phospholipids species
US8262900B2 (en) 2006-12-14 2012-09-11 Life Technologies Corporation Methods and apparatus for measuring analytes using large scale FET arrays
CN102027019A (en) * 2007-12-12 2011-04-20 大学健康网络 High-density lipoprotein-like peptide-phospholipid scaffold (''HPPS'') nanoparticles
CN101485887B (en) * 2008-01-17 2011-06-29 中国人民解放军第二军医大学 5-fluorouracil-sn2-phosphatidyl choline copolymer as well as preparation method and application thereof
CN102843922B (en) * 2010-05-13 2015-12-16 尼特罗米加公司 The neuroprotective of Xiao base Zhi Fang Suan – cognitive decline and/or suppression
EP2646056A1 (en) * 2010-12-02 2013-10-09 Ben Gurion University of the Negev Research and Development Authority Conjugates of a phospholipid and a drug for the treatment of inflammatory bowel disease
KR101315483B1 (en) * 2011-06-23 2013-10-07 주식회사 아리바이오 A composition comprising antibiotics and lysophosphatidylcholine for enhancing immune or treating bacterial infection
KR20140093347A (en) * 2013-01-15 2014-07-28 삼성전자주식회사 Genes inducing agonistic effects by anti-c-Met antibody treatment and drug method using thereof
WO2014205338A2 (en) * 2013-06-21 2014-12-24 President And Fellows Of Harvard College Methods and compositions relating to modulation of the permeability of the blood brain barrier
US20160208329A1 (en) * 2013-09-06 2016-07-21 Cedars-Sinai Medical Center Systems, devices and methods for anti-tl1a therapy
EP3049429B1 (en) * 2013-09-26 2020-05-06 National University of Singapore Compositions and methods utilizing lysophosphatidylcholine scaffolds

Also Published As

Publication number Publication date
WO2015048554A1 (en) 2015-04-02
EP3049429A1 (en) 2016-08-03
AU2019201000A1 (en) 2019-03-07
EP3760638A2 (en) 2021-01-06
AU2021269324A1 (en) 2021-12-09
US10175256B2 (en) 2019-01-08
US20170067919A1 (en) 2017-03-09
AU2014324651A1 (en) 2016-04-14
CA2925613A1 (en) 2015-04-02
EP3049429A4 (en) 2017-08-02
CN105764917A (en) 2016-07-13
JP2020141676A (en) 2020-09-10
CN105764917B (en) 2021-10-08
ES2806751T3 (en) 2021-02-18
EP3760638A3 (en) 2021-05-26
JP2022121623A (en) 2022-08-19
US20190277866A1 (en) 2019-09-12
AU2014324651B2 (en) 2019-03-14
CN113908296A (en) 2022-01-11
JP2016534747A (en) 2016-11-10
JP6692748B2 (en) 2020-05-13
EP3049429B1 (en) 2020-05-06

Similar Documents

Publication Publication Date Title
IL273205A (en) Compositions and methods
HK1218837A1 (en) Compositions and methods
HK1218560A1 (en) Compositions and methods
GB2520795B (en) Compositions and methods
IL265876A (en) Compositions comprising 15-ohepa and methods of using the same
SG11201602331QA (en) Compositions and methods utilizing lysophosphatidylcholine scaffolds
HK1214171A1 (en) Cenicriviroc compositions and methods of making and using the same
GB201308072D0 (en) Compositions and methods
GB201304662D0 (en) Compositions
GB201317636D0 (en) Scaffold
IL276126B (en) Compositions comprising l-4-chlorokynurenine and uses thereof
GB201305813D0 (en) Compositions and methods
GB201310350D0 (en) Curable compositions and membranes
GB201322456D0 (en) Radiotracer compositions and methods
EP2964610A4 (en) Vinylsulfone-based 18f-labeling compositions and methods and uses thereof
HK1226050B (en) Purification method and compositions
PL3030719T3 (en) Scaffold
GB201322617D0 (en) Methods and compositions
GB201312393D0 (en) Compositions and Methods
GB201308242D0 (en) Compositions and uses thereof
GB201300628D0 (en) Compositions comprising 15-OHEPA and methods of using the same
HU4298U (en) Equipment for enhancing of cross-section in chimneys
GB201318736D0 (en) Curable compositions and membranes
GB201304927D0 (en) Compositions